PMID- 11271404
OWN - NLM
STAT- MEDLINE
DCOM- 20010517
LR  - 20190726
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 153
IP  - 3
DP  - 2001 Jan
TI  - Alterations in diurnal and nocturnal locomotor activity in rats treated with a 
      monoamine-depleting regimen of methamphetamine or 
      3,4-methylenedioxymethamphetamine.
PG  - 321-6
AB  - RATIONALE: The long-term neurochemical effects produced by the repeated 
      administration of methamphetamine (MA) and 3,4-methylenedioxymethamphetamine 
      (MDMA) are well documented; however, the functional consequences have not been 
      clearly defined. OBJECTIVE: The present study was designed to investigate whether 
      rats treated with a monoamine-depleting regimen of MA or MDMA exhibit 
      disturbances in locomotor activity during the diurnal and nocturnal cycles. 
      METHODS: Rats were treated with the vehicle or a monoamine-depleting regimen of 
      MA or MDMA (10 mg/kg, IP, every 2 h for four injections on a single day). One 
      week after drug treatment, the rats were placed in residential activity chambers 
      and their locomotor activity was monitored for the next 7-day/night cycles. 
      RESULTS: MA-treated rats exhibited depletions of striatal dopamine and serotonin 
      content of approximately 70%, whereas MDMA-treated rats showed depletions of 
      striatal serotonin content of approximately 50%. Rats treated with MA 
      demonstrated a significant reduction in diurnal, but not nocturnal, locomotor 
      activity, whereas MDMA-treated rats exhibited significant reductions in both 
      diurnal and nocturnal locomotor activity. Analysis of the difference in activity 
      between the nocturnal and diurnal cycles revealed that MA-treated animals 
      exhibited a significantly greater change in activity as compared to that observed 
      in vehicle- and MDMA-treated rats. CONCLUSIONS: Although it is unknown whether 
      the adaptations in locomotor activity observed in MA- and MDMA-treated rats are 
      due to the loss of dopamine and/or serotonin, these data suggest that the 
      administration of a monoamine-depleting regimen of MA or MDMA results in 
      alterations in light-cycle-dependent locomotor activity.
FAU - Wallace, T L
AU  - Wallace TL
AD  - Neuroscience Graduate Program, University of Cincinnati, Ohio, USA.
FAU - Gudelsky, G A
AU  - Gudelsky GA
FAU - Vorhees, C V
AU  - Vorhees CV
LA  - eng
GR  - DA05851/DA/NIDA NIH HHS/United States
GR  - DA06733/DA/NIDA NIH HHS/United States
GR  - DA07427/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 (Biogenic Monoamines)
RN  - 0 (Dopamine Agents)
RN  - 44RAL3456C (Methamphetamine)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - ML1I4KK67B (3,4-methylenedioxyethamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analogs & derivatives/*pharmacology
MH  - Animals
MH  - Biogenic Monoamines/metabolism
MH  - *Circadian Rhythm/physiology
MH  - Dopamine Agents/*pharmacology
MH  - Male
MH  - Methamphetamine/*pharmacology
MH  - Motor Activity/*drug effects/physiology
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2001/03/29 10:00
MHDA- 2001/05/18 10:01
CRDT- 2001/03/29 10:00
PHST- 2001/03/29 10:00 [pubmed]
PHST- 2001/05/18 10:01 [medline]
PHST- 2001/03/29 10:00 [entrez]
AID - 10.1007/s002130000578 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2001 Jan;153(3):321-6. doi: 10.1007/s002130000578.